BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 29501865)

  • 1. Nitric oxide donors for prostate and bladder cancers: Current state and challenges.
    Seabra AB; Durán N
    Eur J Pharmacol; 2018 May; 826():158-168. PubMed ID: 29501865
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Small molecules for great solutions: Can nitric oxide-releasing nanomaterials overcome drug resistance in chemotherapy?
    Pieretti JC; Pelegrino MT; Nascimento MHM; Tortella GR; Rubilar O; Seabra AB
    Biochem Pharmacol; 2020 Jun; 176():113740. PubMed ID: 31786262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitizing activities of nitric oxide donors for cancer resistance to anticancer therapeutic drugs.
    Bonavida B
    Biochem Pharmacol; 2020 Jun; 176():113913. PubMed ID: 32173364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nitric oxide donors: novel cancer therapeutics (review).
    Huerta S; Chilka S; Bonavida B
    Int J Oncol; 2008 Nov; 33(5):909-27. PubMed ID: 18949354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of nitric oxide is a good therapeutic target for bladder tumors that express iNOS.
    Belgorosky D; Langle Y; Prack Mc Cormick B; Colombo L; Sandes E; Eiján AM
    Nitric Oxide; 2014 Jan; 36():11-8. PubMed ID: 24211345
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The regulation of nitric oxide in tumor progression and therapy.
    Hu Y; Xiang J; Su L; Tang X
    J Int Med Res; 2020 Feb; 48(2):300060520905985. PubMed ID: 32090657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitric oxide signaling in human ovarian cancer: A potential therapeutic target.
    El-Sehemy A; Postovit LM; Fu Y
    Nitric Oxide; 2016 Apr; 54():30-7. PubMed ID: 26891890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of TGF-beta1 gene transcription in human prostate cancer cells by nitric oxide.
    Wang D; Lu S; Dong Z
    Prostate; 2007 Dec; 67(16):1825-33. PubMed ID: 17941092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solid tumor physiology and hypoxia-induced chemo/radio-resistance: novel strategy for cancer therapy: nitric oxide donor as a therapeutic enhancer.
    Yasuda H
    Nitric Oxide; 2008 Sep; 19(2):205-16. PubMed ID: 18503779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitric oxide in cancer therapeutics: interaction with cytotoxic chemotherapy.
    Hirst D; Robson T
    Curr Pharm Des; 2010; 16(4):411-20. PubMed ID: 20236069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitric Oxide Donor-Based Cancer Therapy: Advances and Prospects.
    Huang Z; Fu J; Zhang Y
    J Med Chem; 2017 Sep; 60(18):7617-7635. PubMed ID: 28505442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nitric oxide releasing nanomaterials for cancer treatment: current status and perspectives.
    Seabra AB; de Lima R; Calderón M
    Curr Top Med Chem; 2015; 15(4):298-308. PubMed ID: 25579351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of nitric oxide in the response to photooxidative stress in prostate cancer cells.
    D'Este F; Della Pietra E; Badillo Pazmay GV; Xodo LE; Rapozzi V
    Biochem Pharmacol; 2020 Dec; 182():114205. PubMed ID: 32828802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Localization and expression of inducible nitric oxide synthase in patients after BCG treatment for bladder cancer.
    Koskela LR; Poljakovic M; Ehrén I; Wiklund NP; de Verdier PJ
    Nitric Oxide; 2012 Oct; 27(3):185-91. PubMed ID: 22819699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High nitric oxide production, secondary to inducible nitric oxide synthase expression, is essential for regulation of the tumour-initiating properties of colon cancer stem cells.
    Puglisi MA; Cenciarelli C; Tesori V; Cappellari M; Martini M; Di Francesco AM; Giorda E; Carsetti R; Ricci-Vitiani L; Gasbarrini A
    J Pathol; 2015 Aug; 236(4):479-90. PubMed ID: 25875314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Applications for nitric oxide in halting proliferation of tumor cells.
    Reynolds MM; Witzeling SD; Damodaran VB; Medeiros TN; Knodle RD; Edwards MA; Lookian PP; Brown MA
    Biochem Biophys Res Commun; 2013 Feb; 431(4):647-51. PubMed ID: 23337501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. iNOS-selective inhibitors for cancer prevention: promise and progress.
    Janakiram NB; Rao CV
    Future Med Chem; 2012 Nov; 4(17):2193-204. PubMed ID: 23190107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled Delivery of Nitric Oxide for Cancer Therapy.
    Alimoradi H; Greish K; Gamble AB; Giles GI
    Pharm Nanotechnol; 2019; 7(4):279-303. PubMed ID: 31595847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Maximizing outcomes in genitourinary cancers across the treatment continuum.
    Fitzpatrick JM; Bellmunt J; Dreicer R; Fleshner NE; Logothetis CJ; Moul JW; Tombal B; Zlotta A
    BJU Int; 2011 Apr; 107 Suppl 2():1-12. PubMed ID: 21382149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling.
    Frederiksen LJ; Sullivan R; Maxwell LR; Macdonald-Goodfellow SK; Adams MA; Bennett BM; Siemens DR; Graham CH
    Clin Cancer Res; 2007 Apr; 13(7):2199-206. PubMed ID: 17404104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.